Turn Therapeutics Inc. successfully began trading on NASDAQ under ticker TTRX on October 8, 2025. The company strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester. Turn Therapeutics entered into a global supply, development, and license agreement with leading medical-surgical product manufacturer Medline. In addition, the company reported financial results for the third quarter of 2025, showing research and development expenses of $158,699 and general and administrative expenses of $1.75 million.

CEO Bradley Burnam highlighted the company’s progress, including the upcoming data release from the lead program in moderate to severe eczema in early 2026. Turn Therapeutics is focusing on developing a portfolio of potential best-in-class products in dermatology. The company has demonstrated extended stability for its Intranasal Vaccine Program and commenced a clinical trial for the first topical IL-36/IL-31 inhibitor for Eczema.

Financially, Turn Therapeutics had $3.11 million in cash and cash equivalents as of September 30, 2025. The company’s total assets amounted to $4.29 million, with total liabilities of $3.79 million and total stockholders’ equity of $504,019. Turn Therapeutics is a biotechnology company developing and commercializing products for dermatology, wound care, and infectious disease, with a commitment to public health innovation. The company has received FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs.

Read more at GlobeNewswire: Turn Therapeutics Reports Third Quarter 2025 Financial